After the release of the evaluation results by an independent third-party review agency regarding Organon's historical biosimilar procurement process, the company's stock price showed a significant upward trend today.

The audit report clearly stated that its past procurement operations complied with regulatory requirements, and no violations were found. This conclusion dispelled market concerns over potential compliance risks, thereby boosting investor confidence. Driven by this positive news, Organon’s stock closed up 1.7% on the day, with trading volume increasing simultaneously. As biosimilars are an important part of the company’s strategic layout, the results of this audit have laid a compliance foundation for its subsequent business expansion. Market analysts believe that this announcement has effectively alleviated investors’ concerns about regulatory risks and provided support for the company’s valuation recovery.